STAAR Surgical Generates $464,000 in Cash from Operations During Thi...(-2.1% (1183) -1.1% (645) ...),Health

Date:11/2/2009

-2.1% (1,183) -1.1% (645) Gain/(loss) on foreign currency 0.4% 200 -0.6% (329) Other income, net 0.2% 122 0.2% 130 --- --- Other (expense) income, net -1.5% (825) -1.2% (706) ---- ---- Loss before provision for income taxes -6.8% (3,791) -22.6% (12,842) Provision for income taxes 1.7% 926 1.6% 893 --- --- Net loss -8.5% $(4,717) -24.2% $(13,735) ======= ======== Loss per share: Basic and diluted $(0.15) $(0.47) ====== ====== Weighted average shares outstanding: Basic and diluted 31,751 29,489 ====== ====== STAAR Surgical Company Global Sales (in 000's) Unaudited Three Months Ended ------------------ September October 2, 26, % Geographic Sales 2009 2008 Change ---- ---- ------ United States 22.2% $4,017 26.2% $4,746 -15.4% Germany 31.3% 5,663 32.3% 5,844 -3.1% Japan 19.3% 3,503 17.3% 3,127 12.0% Korea 5.9% 1,064
'/>"/>

SOURCE STAAR Surgical Company Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Related medicine technology :

1. STAAR Surgical to Present at the 20th Annual Oppenheimer Healthcare Conference in New York
2. STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call
3. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
4. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
5. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
6. New Non-Surgical Stem-Cell Procedure to Relieve Chronic Tendon Problems
7. Ceremeds OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds
8. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
9. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
10. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
11. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery